Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q1- Text added to 2022 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
Antitrust, billion, borne, cap, capped, Circuit, clearance, codified, daily, deruxtecan, enrichment, exemption, FDARA, fewer, flux, gene, genetic, GlaxoSmithKline, heading, HSR, imminently, immunological, inhibitor, memory, microtubule, outlined, overexpressed, par, percent, pertuzumab, readily, Reauthorization, reclassify, reevaluate, repaid, Secretary, show, simultaneously, solid, suggest, suggesting, trastuzumab, true, underwriting, unrealized, vector
Removed:
auditing, beginning, letter, study
Valuein 2022 Q1 filing- Value in 2022 Q2 filing
Original filings
Filing view